Software as a Medical Device executes clinical decisions across millions of patients. Regulators require post-market surveillance, predetermined change control plans, and continuous algorithm monitoring. The EU AI Act enforcement begins August 2026. EU MDR compliance deadline is 2027. FDA issued its first AI-specific warning letter in April 2026. The governance gap between what algorithms decide and what compliance covers is a patient safety risk.
A CPAP recall affected 15 million devices, caused 561 reported deaths, and cost $1.1B+. A widely deployed sepsis prediction model achieved only 14.7% sensitivity in independent validation -- missing two-thirds of sepsis patients across hundreds of hospitals. An oncology AI recommended unsafe treatments after being trained on synthetic data, resulting in a $4B+ write-off. In every case, the algorithm executed as designed. What failed was governance -- no behavioral monitoring, no drift detection, no population validation, no kill switch.
Every medical device platform governs the algorithm's output: sensitivity, specificity, AUC. No platform governs the algorithm's behavior: diagnostic drift, population shift, dosage boundary violations, unauthorized model updates. Agentomy closes that gap.
Every pattern references a documented incident, a specific regulatory requirement, and a concrete detection method. The 21-method behavioral monitor runs continuously across the device software lifecycle. No theoretical threats. No generic compliance language.
Each layer enforces one aspect of SaMD governance -- from individual clinical decision validation to fleet-wide emergency halt across all connected devices.
Every control mapping references the actual regulatory document. No generic compliance language. All mappings are self-assessed, pending external validation. Penalty exposure ranges from FDA warning letters to EUR 35M under the EU AI Act.
| Framework | Deadline | Scope |
|---|---|---|
| FDA PCCP Guidance | Final Dec 2024 | Predetermined change control plans for all AI-enabled device software. Allows post-market model changes without new 510(k) -- if validated within plan. |
| EU MDR 2017/745 | 2027 | Full application for SaMD. Article 17 (software reliability), Rule 11 (SaMD classification), Articles 83-86 (post-market surveillance). Legacy MDD certificates expiring. |
| EU AI Act (2024/1689) | Aug 2026 / Aug 2027 | SaMD classified as high-risk under Article 6(1). Risk management, transparency, human oversight required. Penalties up to EUR 35M or 7% global turnover. |
| FDA 21 CFR Part 11 | Active | Electronic records and signatures. Requires audit trails, access controls, system validation. Every governance action must be signed and immutable. |
| HIPAA Security Rule | Active (updates 2026) | Protects ePHI. Proposed 2024 updates eliminate addressable/required distinction -- all safeguards mandatory. $100-$50K per violation, criminal penalties up to 10 years. |
| FDA QMSR (21 CFR 820) | Feb 2026 | Quality Management System Regulation incorporating ISO 13485 by reference. Design controls, CAPA, complaint handling. 47 FDA warning letters in FY2024 (96% YoY increase). |
| ISO 13485:2016 | Active | Medical device QMS. Required for CE marking (EU), FDA compliance (US via QMSR), and most international markets. Non-compliance means you cannot sell. |
| IEC 62304 | Active | Medical device software lifecycle processes. Software safety classification (A/B/C). Required for EU MDR compliance and FDA recognized consensus standard. |
| IEC 82304-1 | Active | Health software product requirements for standalone software. Product-level safety, quality, and security through lifecycle. Required for EU market access. |
| FDA AI/ML Action Plan | Ongoing | Five-part framework. Part 5 (real-world performance monitoring) is Agentomy's direct market. PCCP guidance, GMLP principles, transparency requirements. |
Detected by: Recall Response Failure, Audit Gap, Algorithm Drift
Detected by: Algorithm Drift, Population Shift, Alert Fatigue, Validation Gap
Detected by: Dosage Boundary Violation, Validation Gap, Population Shift
Connect any clinical platform through the protocol that fits your infrastructure. Gate mode for pre-decision authorization. Observer mode for post-market monitoring. Both modes produce the same audit trail.
Suite 8: Medical Device SaMD Governance. 20 self-contained, idempotent scenarios across 4 coverage areas: authorization (5), audit trail (5), clinical boundary enforcement (5), and behavioral monitoring (5). Every scenario runs against the live governance layer. No mocks. No stubs.
EU AI Act enforcement begins August 2026. EU MDR compliance deadline is 2027. FDA issued its first AI-specific warning letter in April 2026. The compliance gap is closing.
Request Access